News for 'Sun Pharma'

Ambitious, futuristic: PM Modi lauds Sitharaman's 9th Budget

Ambitious, futuristic: PM Modi lauds Sitharaman's 9th Budget

Rediff.com1 Feb 2026

Reiterating Sitharaman's statement that this is a youth power budget, Modi emphasised that the provisions made in the budget will prepare leaders, innovators and creators across different sectors.

Budget 2026: Time To Fix The Weak Link In R&D Ecosystem

Budget 2026: Time To Fix The Weak Link In R&D Ecosystem

Rediff.com31 Jan 2026

Restoring weighted tax deductions and adopting a petty patents regime can foster firm-level innovative activity critical for competitiveness, points out Nagesh Kumar.

'Money Comes Only When Markets Do Well'

'Money Comes Only When Markets Do Well'

Rediff.com4 Feb 2026

'Given that India underperformed emerging markets by 28 per cent in 2025, the worst performance in over 30 years, the timing of the sharp STT hike could have been better.'

Stock markets end higher on rally in Infosys shares

Stock markets end higher on rally in Infosys shares

Rediff.com16 Jan 2026

Tech Mahindra, HCL Tech, State Bank of India, UltraTech Cement and HDFC Bank were also among the gainers. In contrast, Eternal, Asian Paints, Bharat Electronics, Sun Pharma and Maruti were among the laggards.

Pharma cos may see short-term price blip: Ind-Ra

Pharma cos may see short-term price blip: Ind-Ra

Rediff.com27 Aug 2025

Any potential tariffs on pharmaceutical imports into the US are unlikely to impact the credit profiles of Indian firms except for a short-term pricing blip, according to a report by India Ratings and Research (Ind-Ra). The report stated that the US generics market contributes around 35 per cent to the total revenue of the leading Indian pharma firms.

25% Donald Trump tariff likely to weigh on pharma margins: Analysts

25% Donald Trump tariff likely to weigh on pharma margins: Analysts

Rediff.com12 Aug 2025

If pharmaceutical exports from India to the US come under a 25 per cent tariff bracket, the impact on earnings before interest, tax, depreciation and amortisation (Ebitda) could be around 5 per cent, felt analysts. This is after assuming that about 75 per cent of the tariff would be passed on.

Dr Reddy's profit down 14% on low Lenalidomide US sales

Dr Reddy's profit down 14% on low Lenalidomide US sales

Rediff.com22 Jan 2026

Pharma major Dr Reddy's Laboratories (DRL) reported a 14 per cent year-on-year (Y-o-Y) drop in consolidated net profit to Rs 1,210 crore in the December quarter of FY 2025-26 (Q3FY26) on low sales of cancer drug Lenalidomide in the North American market. The firm's revenue from operations grew to Rs 8,727 crore in Q3FY26, a 4.4 per cent Y-o-Y increase from Rs 8,357 crore recorded for the same quarter last year.

Sensex slips 43 pts; IT shares fall on profit-taking

Sensex slips 43 pts; IT shares fall on profit-taking

Rediff.com23 Dec 2025

Among Sensex firms, Infosys, Bharti Airtel, Adani Ports, Sun Pharma, Tech Mahindra, Eternal, Axis Bank and Maruti were the major laggards. However, ITC, UltraTech Cement, Tata Steel and HDFC Bank were among the gainers.

Sensex, Nifty tank nearly 1%

Sensex, Nifty tank nearly 1%

Rediff.com9 Jan 2026

From the 30-Sensex firms, NTPC, ICICI Bank, Adani Ports, Bharti Airtel, Sun Pharma and Bajaj Finance were among the biggest laggards. However, Asian Paints, HCL Tech, Bharat Electronics and Reliance Industries were among the gainers.

Patients to benefit from GST cut, but pharma firms may face margin pressure

Patients to benefit from GST cut, but pharma firms may face margin pressure

Rediff.com12 Sep 2025

The rationalisation of goods and services tax (GST), announced on Wednesday, directly lowers the cost of everyday medical consumables, and also high-end therapies in oncology and rare diseases, helping reduce out-of-pocket patient expenditure and better adherence to medication.

India, EU free trade deal to likely conclude on Jan 27

India, EU free trade deal to likely conclude on Jan 27

Rediff.com25 Jan 2026

India and the European Union are set to announce on January 27 the conclusion of negotiations and finalisation of a free trade agreement, which is aimed at boosting economic ties between the two regions amid disruptions in global trade due to US tariffs, an official said.

Coldrif syrup maker used industrial-grade materials: ED

Coldrif syrup maker used industrial-grade materials: ED

Rediff.com3 Dec 2025

An Enforcement Directorate (ED) probe has revealed that the manufacturer of Coldrif syrup, linked to the deaths of at least 20 children in Madhya Pradesh, used industrial-grade raw materials without quality checks. The investigation also found that Tamil Nadu Drugs Control Department officials were in frequent contact with the company but failed to conduct mandated inspections.

'Good night, Happy New Year': Maduro's 1st words after US capture

'Good night, Happy New Year': Maduro's 1st words after US capture

Rediff.com4 Jan 2026

The Venezuelan President and his wife Cilia Flores were earlier captured from Caracas after US President Donald Trump unilaterally sanctioned a military operation on Venezuelan soil.

Stock markets surge nearly 1% on last trading session of 2025

Stock markets surge nearly 1% on last trading session of 2025

Rediff.com31 Dec 2025

From the 30-Sensex firms, Tata Steel, Kotak Mahindra Bank, Reliance Industries, Axis Bank, Titan and Trent were among the biggest gainers. However, Tata Consultancy Services, Tech Mahindra, Infosys, Bajaj Finance and Sun Pharma, were the laggards.

Sensex sheds 367 points on foreign fund outflows

Sensex sheds 367 points on foreign fund outflows

Rediff.com26 Dec 2025

From the 30-Sensex firms, Bajaj Finance, Asian Paints, HCL Tech, Tata Consultancy Services, Eternal and Sun Pharma were among the biggest laggards. However, Titan, NTPC, Axis Bank, UltraTech Cement, Reliance Industries and Hindustan Unilever were the gainers.

Sigachi Industries CEO held over Telangana plant blast

Sigachi Industries CEO held over Telangana plant blast

Rediff.com28 Dec 2025

A top executive of Sigachi Industries has been arrested in connection with the explosion at its pharma plant in Telangana in June, which resulted in 54 deaths.

Maduro, wife to appear in New York court today

Maduro, wife to appear in New York court today

Rediff.com5 Jan 2026

Venezuelan President Nicolas Maduro and his wife, Cilia Flores, are set to appear before a federal judge on Monday, after United States authorities confirmed that the case will be heard in the Southern District of New York on Sunday, CBS News reported.

Sensex down 376 points on selling in RIL, HDFC Bank

Sensex down 376 points on selling in RIL, HDFC Bank

Rediff.com6 Jan 2026

Reliance Industries cracked 4.42 per cent, while ITC, Kotak Mahindra Bank, InterGlobe Aviation, and HDFC Bank were also among the laggards. However, ICICI Bank, Sun Pharma, Hindustan Unilever, and State Bank of India were among the gainers.

Paid Rs 1.35L Insurance Premium: 'Can I Get It Back?'

Paid Rs 1.35L Insurance Premium: 'Can I Get It Back?'

Rediff.com8 Jan 2026

Ask rediffGURU Naveenn Kummar your insurance mutual fund and personal finance-related questions.

Now, Isn't Shruti Sweet?

Now, Isn't Shruti Sweet?

Rediff.com22 Dec 2025

Shruti Ramachandran's style lives in that sweet spot where simplicity meets a quiet edge.

Can MFN Pricing Reshape India-US Pharma Equation?

Can MFN Pricing Reshape India-US Pharma Equation?

Rediff.com5 Jun 2025

US accounts for a large part of revenue for top Indian pharma companies like Gland Pharma (54 percent), Dr Reddy's (53 per cent), and Aurobindo Pharma (48 per cent).

Pharma Inc hopes for fair deal as Donald Trump announces 25% tariffs

Pharma Inc hopes for fair deal as Donald Trump announces 25% tariffs

Rediff.com31 Jul 2025

India's pharmaceuticals and medical devices industries are still hopeful that trade negotiations with the US could cut a fairer deal for both sides, after President Donald Trump announced a 25 per cent tariff rate on India on a social networking platform without divulging the finer details.

Sensex down 78 points on weak global trends

Sensex down 78 points on weak global trends

Rediff.com18 Dec 2025

Among Sensex firms, Sun Pharma, Tata Steel, Power Grid, Asian Paints, NTPC and Bharti Airtel were the biggest laggards. Tata Consultancy Services, Tech Mahindra, Infosys, Adani Ports, Axis Bank and HCL Tech were among the gainers.

Sensex jumps 448 points on fresh fund inflows

Sensex jumps 448 points on fresh fund inflows

Rediff.com19 Dec 2025

From the 30-Sensex firms, Bharat Electronics, Power Grid, Tata Motors Passenger Vehicles, Asian Paints, Reliance Industries, and Bajaj Finserv were among the biggest gainers. However, HCL Tech, Kotak Mahindra Bank, ICICI Bank, and Sun Pharma were the laggards.

Stock markets end lower in volatile trade

Stock markets end lower in volatile trade

Rediff.com24 Dec 2025

From the 30-Sensex firms, InterGlobe Aviation, Sun Pharma, Asian Paints, Reliance Industries, Hindustan Unilever, and Tata Steel were among the biggest laggards. However, Trent, UltraTech Cement, Maruti, and Power Grid were among the gainers.

Healthcare IPOs See A Surge In 2025

Healthcare IPOs See A Surge In 2025

Rediff.com8 Jan 2026

The surge has come alongside a decline in average issue sizes and more muted listing-day returns compared with last year.

Weightloss Drugs Hit 1,000 Crore Mark

Weightloss Drugs Hit 1,000 Crore Mark

Rediff.com22 Dec 2025

'As more patients are prescribed these drugs, intolerance due to gastrointestinal and other side effects will become more visible, leading to higher discontinuation rates.'

'14+ Anti-Obesity Drugs In The Pipeline'

'14+ Anti-Obesity Drugs In The Pipeline'

Rediff.com13 Dec 2025

The semaglutide patent expiry next year could unleash a wave of generic versions from Indian drugmakers, with prices expected to go lower -- at least 80 per cent.

Cancer Therapies Break New Ground

Cancer Therapies Break New Ground

Rediff.com26 Dec 2025

'India is clearly moving toward more targeted treatment pathways in high-burden cancers.'

Ozempic launched in India, priced at Rs 2,200 per week

Ozempic launched in India, priced at Rs 2,200 per week

Rediff.com12 Dec 2025

Danish pharma major Novo Nordisk on Friday launched its blockbuster type 2 diabetes treatment injection Ozempic, globally popular for its weight-loss benefits.

Sensex jumps nearly 450 pts on buying in metal shares

Sensex jumps nearly 450 pts on buying in metal shares

Rediff.com12 Dec 2025

Among Sensex firms, Tata Steel, Eternal, UltraTech Cement, Larsen & Toubro, Maruti and Bharti Airtel were the major gainers. However, Hindustan Unilever, Sun Pharma, ITC and Asian Paints were among the laggards.

Cough syrup deaths: Pharma co to face criminal action

Cough syrup deaths: Pharma co to face criminal action

Rediff.com8 Oct 2025

Tamil Nadu Government will take criminal action against a drug manufacturer, whose cough syrup has been banned in the wake of children's deaths in Madhya Pradesh, state minister Ma Subramanian said here on Wednesday.

Kapil Sharma-Priyanka Provide The Laughs On OTT

Kapil Sharma-Priyanka Provide The Laughs On OTT

Rediff.com19 Dec 2025

It's raining sequels on OTT this week, but that's not all. Sukanya Verma lists everything you can watch.

Indian pharma firms not copying products of Swiss cos: Goyal

Indian pharma firms not copying products of Swiss cos: Goyal

Rediff.com10 Jun 2025

Dismissing allegations that Indian phacosrmaceutical companies copy products of Swiss firms, Commerce and Industry Minister Piyush Goyal on Tuesday said it is a long-standing myth and India respects intellectual property rights and never steals technology from others. He said that Swiss pharmaceutical companies have not shown even a single instance that Indian companies have illegally copied any of their trademarks or patents or copyrighted technology.

Will India continue to remain an attractive FDI destination in 2026?

Will India continue to remain an attractive FDI destination in 2026?

Rediff.com27 Dec 2025

FDI inflows into India are expected to register robust growth in 2026, supported by strong macroeconomic fundamentals, big-ticket investment announcements, sustained efforts to improve the ease of doing business, and a new generation of investment-linked trade pacts.

Sensex climbs over 158 points on buying in tech and IT shares

Sensex climbs over 158 points on buying in tech and IT shares

Rediff.com4 Dec 2025

Tata Consultancy Services, Tech Mahindra, Infosys, HCL Tech, Bharti Airtel, Sun Pharma, Bharat Electronics and Trent were the major gainers among Sensex scrips. However, Maruti, Eternal, Kotak Mahindra Bank and Titan were among the laggards.

Trump slaps 100% tariffs on imported pharma products

Trump slaps 100% tariffs on imported pharma products

Rediff.com26 Sep 2025

United States President Donald Trump on Friday announced that his administration will impose a 100 per cent tariff on branded and patented pharmaceutical products beginning October 1, 2025, unless the manufacturing companies are building production facilities in the US.

Sensex climbs 304 pts on buying in metal, auto and pharma shares

Sensex climbs 304 pts on buying in metal, auto and pharma shares

Rediff.com13 Aug 2025

Among Sensex firms, Bharat Electronics, Eternal, Mahindra & Mahindra, Kotak Mahindra Bank, Tata Motors and Power Grid were the gainers. However, Adani Ports, ITC, UltraTech Cement and Titan were among the laggards.

Stock markets end flat in highly volatile trade

Stock markets end flat in highly volatile trade

Rediff.com28 Nov 2025

Among Sensex firms, Power Grid, Eternal, Bharti Airtel, Axis Bank and Infosys were the biggest laggards. However, Mahindra & Mahindra, Sun Pharma, Kotak Mahindra Bank and State Bank of India were among the major gainers.

No deaths due to codeine syrup, accused linked to SP: Yogi

No deaths due to codeine syrup, accused linked to SP: Yogi

Rediff.com22 Dec 2025

Uttar Pradesh Chief Minister Yogi Adityanath on Monday strongly rebutted allegations by Leader of Opposition Mata Prasad Pandey over 'deaths' allegedly due to the consumption of fake medicines and codeine syrup, asserting in the Assembly that no such case has come to the notice of the state government so far.